Clinical trial
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary…
NCT00466921 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00466921 |
|---|---|
| Title | Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome |
| Official title | Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | lenalidomide |
| Enrollment | 33 |
| Start date | Apr 19, 2005 |
| Primary completion | Apr 5, 2010 |
| Completion | May 17, 2013 |
| First posted | Apr 27, 2007 |
| Last update posted | Dec 1, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: